Antibiotic Pipeline Revival: FDA Approves Cubist Pharmaceuticals' SIVEXTRO™ For MRSA, Other Serious Skin Infections

Late this afternoon, the U.S. Food and Drug Administration approved Cubist Pharmaceuticals’ tedizolid phosphate (SIVEXTRO™) for the treatment of acute adult bacterial skin and skin structure infections, or ABSSSIs.